Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
CTOT- Cognition and FDA align on enriched population, study design, and endpoints -
August 12, 2025Clinical
Read more →